Literature DB >> 21324360

Paradoxical function of orexin/hypocretin circuits in a mouse model of Huntington's disease.

Rhîannan H Williams1, A Jennifer Morton, Denis Burdakov.   

Abstract

Huntington's disease (HD) is a neurodegenerative disorder involving progressive motor disturbances, cognitive decline, and desynchronized sleep-wake rhythms. Recent studies revealed that restoring normal sleep-wake cycles can improve cognitive function in HD mice, suggesting that some sleep/wake systems remain operational and thus represent potential therapeutic targets for HD. Hypothalamic neurons expressing orexins/hypocretins (orexin neurons) are fundamental orchestrators of arousal in mammals, but it is unclear whether orexin circuits operate normally in HD. Here we analyzed the electrophysiology, histology, and gene expression of orexin circuits in brain slices from R6/2 mice, a transgenic model of HD with a progressive neurological phenotype. We report that in R6/2 mice, the size of an electrically distinct subpopulation of orexin neurons is reduced, as is the number of orexin-immunopositive cells in some hypothalamic regions. R6/2 orexin cells display altered glutamatergic inputs, and have an abnormal circadian profile of activity, despite normal circadian rhythmicity of the suprachiasmatic nucleus (SCN), the "master clock" of the brain. Nevertheless, even at advanced stages of HD, intrinsic firing properties of orexin cells remain normal and suppressible by serotonin, noradrenaline, and glucose. Furthermore, histaminergic neurons (key cells required for the propagation of orexin-induced arousal) also display normal responses to orexin. Together, these data suggest that the orexin system remains functional and modifiable in HD mice, although its circadian activity profile is disrupted and no longer follows that of the SCN.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21324360      PMCID: PMC5767114          DOI: 10.1016/j.nbd.2011.02.006

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  55 in total

1.  Physiological changes in glucose differentially modulate the excitability of hypothalamic melanin-concentrating hormone and orexin neurons in situ.

Authors:  Denis Burdakov; Oleg Gerasimenko; Alexei Verkhratsky
Journal:  J Neurosci       Date:  2005-03-02       Impact factor: 6.167

2.  High Fos expression during the active phase in orexin neurons of a diurnal rodent, Tamias sibiricus barberi.

Authors:  Tohru Kodama; Setsuo Usui; Yoshiko Honda; Mayumi Kimura
Journal:  Peptides       Date:  2004-12-29       Impact factor: 3.750

3.  Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity.

Authors:  J Hara; C T Beuckmann; T Nambu; J T Willie; R M Chemelli; C M Sinton; F Sugiyama; K Yagami; K Goto; M Yanagisawa; T Sakurai
Journal:  Neuron       Date:  2001-05       Impact factor: 17.173

4.  Fos expression in orexin neurons varies with behavioral state.

Authors:  I V Estabrooke; M T McCarthy; E Ko; T C Chou; R M Chemelli; M Yanagisawa; C B Saper; T E Scammell
Journal:  J Neurosci       Date:  2001-03-01       Impact factor: 6.167

5.  Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease.

Authors:  A Jennifer Morton; Nigel I Wood; Michael H Hastings; Carrie Hurelbrink; Roger A Barker; Elizabeth S Maywood
Journal:  J Neurosci       Date:  2005-01-05       Impact factor: 6.167

6.  Management of sleep/wake cycles improves cognitive function in a transgenic mouse model of Huntington's disease.

Authors:  Patrick N Pallier; A Jennifer Morton
Journal:  Brain Res       Date:  2009-05-18       Impact factor: 3.252

7.  Orexin neurons are necessary for the circadian control of REM sleep.

Authors:  Sandor Kantor; Takatoshi Mochizuki; Agnieszka M Janisiewicz; Erika Clark; Seiji Nishino; Thomas E Scammell
Journal:  Sleep       Date:  2009-09       Impact factor: 5.849

8.  Circadian rhythms of basal orexin levels in the hypothalamus are not influenced by an impaired corticotropin-releasing hormone receptor type 1 system.

Authors:  Thomas Fenzl; Cornelia Flachskamm; Maria Rossbauer; Jan M Deussing; Mayumi Kimura
Journal:  Behav Brain Res       Date:  2009-04-18       Impact factor: 3.332

9.  Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6/2 mice.

Authors:  A Jennifer Morton; Dervila Glynn; Wendy Leavens; Zhiguang Zheng; Richard L M Faull; Jeremy N Skepper; James M Wight
Journal:  Neurobiol Dis       Date:  2008-12-11       Impact factor: 5.996

10.  Hypothalamic orexin neurons regulate arousal according to energy balance in mice.

Authors:  Akihiro Yamanaka; Carsten T Beuckmann; Jon T Willie; Junko Hara; Natsuko Tsujino; Michihiro Mieda; Makoto Tominaga; Ken ichi Yagami; Fumihiro Sugiyama; Katsutoshi Goto; Masashi Yanagisawa; Takeshi Sakurai
Journal:  Neuron       Date:  2003-06-05       Impact factor: 17.173

View more
  16 in total

1.  Optogenetic-mediated release of histamine reveals distal and autoregulatory mechanisms for controlling arousal.

Authors:  Rhannan H Williams; Melissa J S Chee; Daniel Kroeger; Loris L Ferrari; Eleftheria Maratos-Flier; Thomas E Scammell; Elda Arrigoni
Journal:  J Neurosci       Date:  2014-04-23       Impact factor: 6.167

2.  Circadian dysfunction in the Q175 model of Huntington's disease: Network analysis.

Authors:  Benjamin Smarr; Tamara Cutler; Dawn H Loh; Takashi Kudo; Dika Kuljis; Lance Kriegsfeld; Cristina A Ghiani; Christopher S Colwell
Journal:  J Neurosci Res       Date:  2019-07-29       Impact factor: 4.164

3.  Dichotomous cellular properties of mouse orexin/hypocretin neurons.

Authors:  Cornelia Schöne; Anne Venner; David Knowles; Mahesh M Karnani; Denis Burdakov
Journal:  J Physiol       Date:  2011-04-11       Impact factor: 5.182

4.  Neurophysiological and Behavioral Effects of Anti-Orexinergic Treatments in a Mouse Model of Huntington's Disease.

Authors:  Magali Cabanas; Cristiana Pistono; Laura Puygrenier; Divyangana Rakesh; Yannick Jeantet; Maurice Garret; Yoon H Cho
Journal:  Neurotherapeutics       Date:  2019-07       Impact factor: 7.620

5.  Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.

Authors:  Jing Jin; Jennifer Albertz; Zhihong Guo; Qi Peng; Gay Rudow; Juan C Troncoso; Christopher A Ross; Wenzhen Duan
Journal:  J Neurochem       Date:  2013-03-05       Impact factor: 5.372

6.  Convergent inputs from electrically and topographically distinct orexin cells to locus coeruleus and ventral tegmental area.

Authors:  J Antonio González; Lise T Jensen; Lars Fugger; Denis Burdakov
Journal:  Eur J Neurosci       Date:  2012-04-16       Impact factor: 3.386

Review 7.  Interactions of the histamine and hypocretin systems in CNS disorders.

Authors:  Ling Shan; Yves Dauvilliers; Jerome M Siegel
Journal:  Nat Rev Neurol       Date:  2015-06-23       Impact factor: 42.937

8.  Abnormally abrupt transitions from sleep-to-wake in Huntington's disease sheep (Ovis aries) are revealed by automated analysis of sleep/wake transition dynamics.

Authors:  William T Schneider; Szilvia Vas; Alister U Nicol; A Jennifer Morton
Journal:  PLoS One       Date:  2021-05-13       Impact factor: 3.240

9.  A unifying computational framework for stability and flexibility of arousal.

Authors:  Christin Kosse; Denis Burdakov
Journal:  Front Syst Neurosci       Date:  2014-10-20

10.  Glutamate and GABA as rapid effectors of hypothalamic "peptidergic" neurons.

Authors:  Cornelia Schöne; Denis Burdakov
Journal:  Front Behav Neurosci       Date:  2012-11-26       Impact factor: 3.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.